

Supplemental table 1. First-line therapies received by patients with bone-predominant mRCC.

TKI or ICI		N (%)
TKI	Sunitinib	19 (47.5)
	Pazopanib	11 (27.5)
	Tivozanib	1 (2.5)
	Sorafenib	2 (5.0)
	Axitinib	1 (2.5)
	Cabozantinib	6 (15.0)
ICI	Nivolumab	8 (27.6)
	Pembrolizumab	1 (3.4)
	Nivolumab + Ipilimumab	20 (69.0)

Supplemental table 2. Subsequent therapies received by patients with bone-predominant mRCC.

Subsequent Treatments	TKI	ICI
Avg. # of subsequent lines	2.36	1.38
TKI	21	14
Anti-PD1/L1	22	3
Anti-PD1/L1 + TKI	6	5
Anti-PD1 + CTLA4	9	0
Anti-PD1 + CTLA4 + TKI	2	0
mTOR inhibitor	5	1
mTOR inhibitor + TKI	6	6
Other	2	2